Rosetta Genomics (OTCPK:ROSG.Q) - Stock Price, News & Analysis

ROSG.Q Stock Overview

Operates as a genomic diagnostics company worldwide. More details

ROSG.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

High level of non-cash earnings

Does not have a meaningful market cap ($592)

Shares are highly illiquid

Rosetta Genomics Ltd. Competitors

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

DermTech

OTCPK:DMTK.Q

US$35.0

ObsEva

OTCPK:OBSE.F

US$117.0

Price History & Performance

Summary of all time highs, changes and price drops for Rosetta Genomics
Historical stock prices
Current Share Price	US$0.0001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	9,900.00%
1 Year Change	n/a
33 Year Change	-94.12%
5 Year Change	-98.04%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ROSG.Q	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how ROSG.Q performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ROSG.Q performed against the US Market.

Price Volatility

Is ROSG.Q's price volatile compared to industry and market?
ROSG.Q volatility
ROSG.Q Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ROSG.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ROSG.Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	n/a	www.rosettagenomics.com

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company’s microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer.

Rosetta Genomics Ltd. Fundamentals Summary

How do Rosetta Genomics's earnings and revenue compare to its market cap?
ROSG.Q fundamental statistics
Market cap	US$592.00
Earnings (TTM)	-US$9.48m
Revenue (TTM)	US$2.86m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ROSG.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ROSG.Q income statement (TTM)
Revenue	US$2.86m
Cost of Revenue	US$1.90m
Gross Profit	US$962.00k
Other Expenses	US$10.45m
Earnings	-US$9.48m

Last Reported Earnings

Jun 30, 2017

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ROSG.Q perform over the long term?

See historical performance and comparison